Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial

Abstract

Keywords

plaque psoriasis maintenance therapy calcipotriol/betamethasone dipropionate foam proactive therapy long-term efficacy safety Canadian subgroup analysis

Get full access to this article

View all access options for this article.

References

De Simone

Dapavo

Malagoli

et al. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach. Int J Dermatol. 2022.doi:10.1111/ijd.16192

35609147

Feldman

SR.

Goffe

Rice

et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504-513.28465778

Bonnekoh

Fernandez-Garcia

JJ.

Surber

Bewley

. Innovation that drives your dermatological future. EMJ Dermatol. 2017;5:36-43.

Lebwohl

Kircik

Lacour

J-P

et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269-1277.doi:10.1016/j.jaad.2020.09.037

32950546

Yusuf

Wittes

. Interpreting geographic variations in results of randomized, controlled trials. N Engl J Med. 2016;375(23):2263-2271.doi:10.1056/NEJMra1510065

27959693

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.36 MB

0.34 MB